NCT01442064View on ClinicalTrials.gov

An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

NACompletedINTERVENTIONAL

Enrollment

608

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Macular EdemaRetinal Vein Occlusion

Interventions

DRUG

Ranibizumab 0.5 mg

Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).